Publications by authors named "M Igari"
Background/aim: Concurrent cisplatin-based chemoradiotherapy (CCRT) is the standard treatment for locally advanced cervical cancer. Especially, CCRT with magnetic resonance imaging (MRI) or computed tomography-based image-guided brachytherapy (CT-based 3D-IGBT) for cervical cancer has resulted in good LC rates. However, progression-free survival (PFS) and overall survival (OS) rates for locally advanced cervical cancer are still low and could be improved.
View Article and Find Full Text PDFArticle Synopsis
- Liraglutide, a long-acting medication for type 2 diabetes, was switched from a DPP4 inhibitor to assess its immediate effects on blood glucose levels in 55 inpatients.
- A study revealed significant reductions in fasting, preprandial, and postprandial blood glucose levels just one day after switching to low-dose (0.3 mg) liraglutide, with no severe hypoglycemia reported.
- The changes in blood glucose levels were not linked to initial hemoglobin A1c values or any specific insulin secretion markers, indicating liraglutide's effectiveness regardless of the previous medication used.
Background: Intensity-modulated radiotherapy (IMRT) has been increasingly used for patients with locally advanced non-small cell lung cancer (LA-NSCLC). However, there are some barriers to implementing IMRT for LA-NSCLC, including the complexity of treatment plan optimization. This study aimed to evaluate the learning curve of lung dose optimization in IMRT for LA-NSCLC and identify the factors that affect the degree of achievement of lung dose optimization.
View Article and Find Full Text PDFBackground/aim: Combined intracavitary and interstitial brachytherapy (IC/IS-BT) is an effective treatment for extensive and bulky cervical cancer. However, the optimum number of interstitial needle applicators ("needles") inserted in IC/IS-BT can be difficult to determine. To examine the number of needles required for adequate dose coverage of cervical tumors, we retrospectively analyzed IC/IS-BT plans.
View Article and Find Full Text PDFArticle Synopsis
- Researchers evaluated the effectiveness and side effects of combining chemoradiotherapy (CCRT) with durvalumab for treating locally advanced non-small cell lung cancer (LA-NSCLC) with N3 lymph node metastasis, comparing it to CCRT alone.
- The study analyzed data from 29 patients who underwent treatment between 2008 and 2022, focusing on local control, progression-free survival, and overall survival, with a median follow-up of 22 months.
- Results showed a significantly higher one-year local control rate for the durvalumab group (89%) compared to the CCRT-alone group (47%), but there was no difference in progression-free or overall survival; however, both groups experienced notable pneumonitis